Comparison of Complication and Readmission Rates Between Robot-Assisted and Open Radical Cystectomy: Results From the Randomized RAZOR Clinical Trial
Purpose:We assessed differences in complications and readmissions between robot-assisted radical cystectomy (RARC) and open radical cystectomy (ORC).Materials and Methods:This study uses data from the per-protocol population of the Randomized Robotic-Assisted vs Open Radical Cystectomy (RAZOR) study...
Saved in:
Published in | The Journal of urology Vol. 213; no. 6; pp. 684 - 692 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
Wolters Kluwer
01.06.2025
|
Subjects | |
Online Access | Get full text |
ISSN | 0022-5347 1527-3792 1527-3792 |
DOI | 10.1097/JU.0000000000004497 |
Cover
Summary: | Purpose:We assessed differences in complications and readmissions between robot-assisted radical cystectomy (RARC) and open radical cystectomy (ORC).Materials and Methods:This study uses data from the per-protocol population of the Randomized Robotic-Assisted vs Open Radical Cystectomy (RAZOR) study, a multicenter, open-label, phase 3, noninferiority clinical trial. RAZOR enrolled across 15 academic medical centers in the United States between 2011 and 2014. The median follow-up was 2 years. Complications up to 90 days using the Clavien-Dindo classification, and readmissions at 90 days and 1 year postoperatively were compared. Multivariable logistic regression analyses were performed to determine any predictors of major complications and of postsurgery readmission.Results:Baseline characteristics were similar, and there was no significant difference in overall and major complication rates between RARC (n = 150) and ORC (n = 152) arms. Simplified frailty index ≥ 3 (HR, 4.22, 95% CI, 2.67-6.66, P < .0001) was a significant predictor of major complications within 90 days. Readmission rates at 90 days were 24.1% for RARC and 23.1% for ORC, and readmission rates at 1 year were 29.5% for RARC and 28.5% for ORC (P = .80). Simplified frailty index ≥ 3 was a significant predictor of readmission at both time points (subdistribution HR 4.43, 95% CI, 1.75-11.2, P = .002 at 90 days and subdistribution HR, 5.28, 95% CI, 2.22-12.6, P < .001, at 1 year).Conclusions:No significant differences in major complications and readmission rates between ORC and RARC were noted. Patient frailty was an important predictor of these outcomes, and special attention needs to be taken in ensuring appropriate patient selection and preoperative preparation.Trial Registration:ClinicalTrials.gov Identifier: NCT01157676 |
---|---|
Bibliography: | Corresponding Author: Dipen J. Parekh, MD, Department of Urology, University of Miami Miller School of Medicine, 1120 NW 14th St, Suite 1551M, Miami, FL 33136 (parekhd@med.miami.eduFunding/Support: The RAZOR trial was supported by the National Institutes of Health (NIH) National Cancer Institute (NCI; Grant No. 5RO1CA155388).Conflict of Interest Disclosures: The Authors have no conflicts of interest to disclose.Ethics Statement: Institutional Review Board approval was taken at each site for the RAZOR trial.Author Contributions:Conception and design: Parekh, Svatek, Venkatramani.Data analysis and interpretation: Parekh, Reis, Gonzalgo, Swain, Venkatramani.Data acquisition: Parekh, Gonzalgo, Swain, Venkatramani.Drafting the manuscript: Parekh, Swain, Venkatramani.Critical revision of the manuscript for scientific and factual content: Parekh, Reis, Gonzalgo, Svatek, Swain, Venkatramani.Statistical analysis: Parekh, Reis, Swain, Venkatramani.Supervision: Parekh, Gonzalgo, Svatek, Swain, Venkatramani. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0022-5347 1527-3792 1527-3792 |
DOI: | 10.1097/JU.0000000000004497 |